INKON Life(300143) 新浪财经·2025-04-01 02:43Core Insights - The company reported a 2024 revenue of 1.559 billion yuan, representing a 6.01% increase, and a net profit of 115 million yuan, reflecting a 14.92% growth, aligning with expectations [1] - The company is actively expanding its oncology medical service network through the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan, which is expected to enhance its capabilities in the oncology sector [3] - The integration of AI in medical services is being prioritized, with significant improvements in operational efficiency and diagnostic capabilities being reported [4] Financial Performance - 2024 revenue reached 1.559 billion yuan (+6.01%), with a net profit of 115 million yuan (+14.92%) and a net cash flow from operations of 259 million yuan (+36.44%) [1] - The gross margin for 2024 was 25.86% (-2.71 percentage points), with the medical services segment at 19.65% (-5.17 percentage points) and the medical devices segment at 46.06% (+5.45 percentage points) [1] - The net profit margin was 7.40% (+0.57 percentage points), while the net profit margin excluding non-recurring items was 5.35% (-1.69 percentage points) [1] Segment Performance - The medical services segment generated 1.192 billion yuan in revenue (+3.76%), with Sichuan Friendship Hospital achieving 579 million yuan (+10.11%) and Suzhou Guangci Hospital at 524 million yuan (-2.67%) [2] - The medical devices segment reported a revenue of 367 million yuan (+14.05%), with Shengnuo Medical at 175 million yuan and Unimedik at 90 million yuan [2] Strategic Initiatives - The acquisition of Changsha Kexin Tumor Hospital is expected to enhance the company's oncology service capabilities and contribute positively to its financial performance [3] - The company is developing an AI-driven medical ecosystem, which includes various applications aimed at improving diagnostic efficiency and operational capabilities [4] Growth Projections - Revenue forecasts for 2025, 2026, and 2027 are projected at 1.877 billion yuan, 2.168 billion yuan, and 2.509 billion yuan, respectively, with net profits expected to be 134 million yuan, 160 million yuan, and 194 million yuan [6]